Shares of Coherus BioSciences (CHRS -7.36%) were sinking 8.6% lower as of 11:14 a.m. ET on Tuesday. The decline followed a nice pop for the stock on Monday after Coherus announced it was selling its Cimerli ophthalmology franchise to Sandoz Group. This deal with Sandoz will allow Coherus to pocket $170 million in cash. The biotech will also receive additional money for its Cimerli product inventory.Are investors conflicted about Coherus' Sandoz deal?It might seem that investors are conflicted about Coherus' ...

Shares of Coherus (CHRS 5.74%) rallied as much as 21.7% early Monday, then gave up its gains to trade up around 2.4% as of 2:40 p.m. ET. This occurred after the company announced an agreement to divest its ophthalmology franchise.Coherus divests a non-core assetIn a press release this morning, Coherus announced a deal to divest its Cimerli franchise, a biosimilar drug to treat vision impairment and loss, to biosimilars company Sandoz Group (SDZN.Y 2.90%). The latter will pay Coherus $170 million in cash up ...

Coherus BioSciences (NASDAQ:CHRS) stock is taking off on Monday after the biopharmaceutical company announced a $170 million divestment.Coherus BioSciences is selling its CIMERLI ophthalmology franchise to Sandoz (OTCMKTS:SDZNY) for an upfront payment of $170 million. That payment will be made in cash and the sale includes supporting commercial infrastructure for CIMERLI.To go along with this, Coherus BioSciences will also sell all CIMERLI product inventory at a later date for additional funds. The sale is ...

– Transaction aligns to Coherus' strategic focus on oncology –– Conference call Monday, January 22, 2024, at 8:30 a.m. Eastern Time – REDWOOD CITY, Calif., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus, NASDAQ:CHRS) today announced it has entered into an agreement to divest its CIMERLI® (ranibizumab-eqrn) ophthalmology franchise, inclusive of CIMERLI and its supporting commercial infrastructure, to Sandoz for upfront, all-cash consideration of $170 million plus an additional amount ...

– Data demonstrate early activity with casdozokitug/atezolizumab/bevacizumab; 38% objective response rate including three complete responses – – Data support casdozo as a promising novel immuno-oncology agent with clinical activity in liver cancer that may be associated with IL-27 pathway biomarkers – – Data support continued evaluation of casdozo with VEGF and PD-(L)1 blockade in HCC, including further clinical development to evaluate casdozokitug/toripalimab/bevacizumab – REDWOOD CITY, Calif., Jan. 18, ...

Coherus BioSciences, Inc. (NASDAQ:CHRS) Q3 2023 Earnings Conference Call November 6, 2023 5:00 PM ET Company Participants Jamie Taylor - Head of Investor Relations Dennis Lanfear - President, CEO and Chairman Paul Reider - Chief Commercial Officer Theresa LaVallee - Chief Development Officer Rosh Dias - Chief Medical Officer McDavid Stilwell - Chief Financial Officer Conference Call Participants Robyn Karnauskas - Truist Securities Yigal Nochomovitz - Citigroup Michael Nedelcovych - TD Cowen Douglas Tsao - ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36721 Coherus BioSciences, Inc. (Exact Name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of ...

Coherus BioSciences, Inc. (NASDAQ:CHRS) Q2 2023 Earnings Conference Call August 2, 2023 5:00 PM ET Company Participants Marek Ciszewski – Senior Vice President-Investor Relations Denny Lanfear – President, CEO and Chairman Paul Reider – Chief Commercial Officer Theresa LaVallee – Chief Development Officer Rosh Dias – Chief Medical Officer McDavid Stilwell – Chief Financial Officer Conference Call Participants Robyn Karnauskas – Truist Securities Michael Nedelcovych – TD Cowen Douglas Tsao – H.C. Wainwright ...

The 2027 Term Loans mature on either (i) the fifth anniversary of the Tranche A Closing Date; or (ii) October 15, 2025, if the outstanding aggregate principal amount of the 2026 Convertible Notes is greater than $50.0 million on October 1, 2025. The 2027 Term Loans accrued interest from inception through March 31, 2023 at 8.25% plus three-month LIBOR per annum with a LIBOR floor of 1.0%; and starting April 1, 2023, accrue interest at 8.25% plus the sum (the "Adjusted Term SOFR") of three-month SOFR and 0.26 ...

Coherus BioSciences, Inc. (NASDAQ:CHRS) Q1 2023 Earnings Conference Call May 8, 2023 5:00 PM ET Company Participants Marek Ciszewski - Investor Relations Denny Lanfear - Chief Executive Officer Theresa Lavallee - Chief Development Officer Rosh Dias - Chief Medical Officer Paul Reider - Chief Commercial Officer McDavid Stilwell - Chief Financial Officer Conference Call Participants Robyn Karnauskas - Truist Securities Salim Syed - Mizuho Mike Nedelcovych - TD Cowen Douglas Tsao - H.C. Wainwright Ash Verma - ...